However, due to the known insulin sensitizing effects of sEH inhibition [41], [42], use of the atherogenic diet model allowed us to evaluate the fundamental pathological role of hepatic inflammation in NAFLD/NASH without the confounding effects of weight gain, adipose tissue inflammation, and insulin resistance. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.